Skip to main content Accessibility help

Pharmacotherapy of schizophrenia: toward a metabolomic-based approach

Published online by Cambridge University Press:  05 June 2018

Haythum O. Tayeb
Department of Medicine, Division of Neurology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Hussam A. Murad
Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia Department of Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Misbahuddin M. Rafeeq
Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia
Frank I. Tarazi
Department of Psychiatry and Neuroscience Program, Harvard Medical School and McLean Hospital, Boston, Massachusetts, USA
E-mail address:


Approximately 20%–30% of schizophrenia patients are resistant to current standard pharmacotherapies. Recent schizophrenia research aims to identify specific pathophysiological abnormalities and novel targets in the disease, with the goals of identifying at-risk individuals, facilitating diagnosis, prompting early and personalized interventions, and helping predict response to treatment. Metabolomics involves the systematic study of the profile of biochemical alterations early in the course of a given disorder. Major aspects of the schizophrenia metabolome have been characterized, uncovering potential selective biomarkers for the disease that may change how the disorder is diagnosed, and how patients are stratified and treated. This review focuses on the most common metabolomic fingerprints of the different pathways involved in the pathophysiology of schizophrenia, and the potential development of novel metabolomic-related pharmacotherapies for improved treatment of schizophrenia and other related idiopathic psychotic disorders.

© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below.


1. Chong, HY, Teoh, SL, Wu, DB-C, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Disease Treat. 2016; 12: 357373.Google ScholarPubMed
2. Emsley, R, Chiliza, B, Asmal, L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013; 13(1): 50.CrossRefGoogle Scholar
3. Hosák, L, Hosakova, J. The complex etiology of schizophrenia—general state of the art. Neuro Endocrinol Lett. 2015; 36(7): 631637.Google ScholarPubMed
4. Karlsgodt, KH, Sun, D, Cannon, TD. Structural and functional brain abnormalities in schizophrenia. Curr Dir Psychol Sci. 2010; 19(4): 226231.CrossRefGoogle Scholar
5. Baldessarini, RJ, Tarazi, FI. Pharmacotherapy of Psychosis and Mania. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2005; 11: 461500.Google Scholar
6. Lewis, DA, Sweet, RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009; 119(4): 706716.CrossRefGoogle ScholarPubMed
7. Lieberman, J, Stroup, T, McEvoy, J, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 12091223.CrossRefGoogle ScholarPubMed
8. Davidson, M, Galderisi, S, Weiser, M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009; 166(6): 675682.CrossRefGoogle Scholar
9. Haddad, PM, Brain, C, Scott, J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014; 5: 4362.CrossRefGoogle ScholarPubMed
10. Jones, KA, Menniti, FS, Sivarao, DV. Translational psychiatry—light at the end of the tunnel. Ann N Y Acad Sci. 2015; 1344(1): 111.CrossRefGoogle ScholarPubMed
11. Atkinson, AJ, Colburn, WA, DeGruttola, VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 8995.Google Scholar
12. Weickert, CS, Weickert, TW, Pillai, A, et al. Biomarkers in schizophrenia: a brief conceptual consideration. Disease Markers. 2013; 35(1): 39.CrossRefGoogle ScholarPubMed
13. Pickard, BS. Schizophrenia biomarkers: translating the descriptive into the diagnostic. J Psychopharmacol. 2015; 29(2): 138143.CrossRefGoogle ScholarPubMed
14. Sethi, S, Brietzke, E. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2016; 19(3): pyv096.CrossRefGoogle Scholar
15. Holmes, E, Wilson, ID, Nicholson, JK. Metabolic phenotyping in health and disease. Cell. 2008; 134(5): 714717.CrossRefGoogle ScholarPubMed
16. Griffiths, WJ, Koal, T, Wang, Y, et al. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010; 49(32): 54265445.CrossRefGoogle ScholarPubMed
17. Orešič, M, Tang, J, Seppänen-Laakso, T, et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011; 3(3): 19.CrossRefGoogle ScholarPubMed
18. Yang, J, Chen, T, Sun, L, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013; 18(1): 6778.CrossRefGoogle ScholarPubMed
19. He, Y, Yu, Z, Giegling, I, et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012; 2(8): e149.CrossRefGoogle Scholar
20. Gan, JL, Cheng, ZX, Duan, HF, et al. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: a magnetic resonance spectroscopy study. Psychiatry Res. 2014; 223(1): 2327.CrossRefGoogle ScholarPubMed
21. Xuan, J, Pan, G, Qiu, Y, et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011; 10(12): 54335443.CrossRefGoogle ScholarPubMed
22. Tkachev, D, Mimmack, ML, Huffaker, SJ, et al. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol. 2007; 10(4): 557563.CrossRefGoogle Scholar
23. Holmes, E, Tsang, TM, Huang, JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006; 3(8): e327.CrossRefGoogle Scholar
24. Kaddurah-Daouk, R, McEvoy, J, Baillie, R, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007; 12(10): 934945.CrossRefGoogle Scholar
25. Cai, HL, Li, HD, Yan, XZ, et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012; 11(8): 43384350.CrossRefGoogle ScholarPubMed
26. Fukushima, T, Iizuka, H, Yokota, A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014; 9(7): e101652.CrossRefGoogle ScholarPubMed
27. Guest, PC, Schwarz, E, Krishnamurthy, D, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011; 36(7): 10921096.CrossRefGoogle ScholarPubMed
28. Palomino, A, González-Pinto, A, Martinez-Cengotita, , et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 44: 2933.CrossRefGoogle ScholarPubMed
29. Beckmann, H, Gattaz, W. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. J Neural Transm. 2002; 109(5): 931938.CrossRefGoogle ScholarPubMed
30. Linderholm, KR, Skogh, E, Olsson, SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2010; 38(3): 426432.CrossRefGoogle ScholarPubMed
31. Ohrmann, P, Kugel, H, Bauer, J, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res. 2008; 106(2): 156163.CrossRefGoogle ScholarPubMed
32. Liu, P, Jing, Y, Collie, N, et al. Altered brain arginine metabolism in schizophrenia. Transl Psychiatry. 2016; 6(8): e871.CrossRefGoogle Scholar
33. Yao, J, Zhou, X, Keshavan, M. Homeostatic imbalance of adenosine signaling and uric acid production in schizophrenia. Schizophr Bull. 2017; 43(Suppl 1): S89.CrossRefGoogle Scholar
34. Chan, MK, Gottschalk, MG, Haenisch, F, et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol. 2014; 122: 4572.CrossRefGoogle Scholar
35. Harris, LW, Guest, PC, Wayland, MT, et al. Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology. 2013; 38(6): 752766.CrossRefGoogle ScholarPubMed
36. Harris, LW, Pietsch, S, Cheng, TM, et al. Comparison of peripheral and central schizophrenia biomarker profiles. PloS One. 2012; 7(10): e46368.CrossRefGoogle ScholarPubMed
37. Plitman, E, Nakajima, S, de la Fuente-Sandoval, C, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol. 2014; 24(10): 15911605.CrossRefGoogle ScholarPubMed
38. Lisman, JE, Coyle, JT, Green, RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008; 31(5): 234242.CrossRefGoogle Scholar
39. Chen, Y, Guillemin, GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009; 2: 119.CrossRefGoogle ScholarPubMed
40. Muller, N, Myint, AM, Schwarz, MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Design. 2011; 17(2): 130136.CrossRefGoogle ScholarPubMed
41. Volk, DW, Gonzalez-Burgos, G, Lewis, DA. l-Proline, GABA synthesis and gamma oscillations in schizophrenia. Trends Neurosci. 2016; 39(12): 797798.CrossRefGoogle Scholar
42. Najjar, S, Pearlman, DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015; 161(1): 102112.CrossRefGoogle ScholarPubMed
43. Calabrese, V, Giordano, J, Crupi, R. Hormesis, cellular stress response and neuroinflammation in schizophrenia: early onset versus late onset state. J Neurosci Res. 2017; 95(5): 11821193.CrossRefGoogle ScholarPubMed
44. Bou Khalil, R. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses. 2011; 77(3): 427429.CrossRefGoogle ScholarPubMed
45. Liu, F, Guo, X, Wu, R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1): 169176.CrossRefGoogle ScholarPubMed
46. Ghanizadeh, A, Dehbozorgi, S, OmraniSigaroodi, M, et al. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov. 2014; 8(3): 211215.CrossRefGoogle ScholarPubMed
47. Zhang, L, Zhao, J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014; 10: 11031111.CrossRefGoogle ScholarPubMed
48. Shim, S, Shuman, M, Duncan, E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophr Res. 2016; 170(1): 226231.CrossRefGoogle ScholarPubMed
49. Breier, A, Hummer, T, Liffick, E, et al. The effects of 12-month, double-blind N-acetyl cysteine treatment on symptoms and brain structures in early phase psychosis. Biol Psychiatry. 2017; 81(10): S164.CrossRefGoogle Scholar
50. Harvey, PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009; 19(3): 324335.CrossRefGoogle Scholar
51. Goff, DC, Romero, K, Paul, J, et al. Biomarkers for drug development in early psychosis: current issues and promising directions. Eur Neuropsychopharmacol. 2016; 26(6): 923937.CrossRefGoogle ScholarPubMed
52. Kegel, ME, Bhat, M, Skogh, E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014; 7: 1522.CrossRefGoogle Scholar
53. Schwarcz, R, Bruno, JP, Muchowski, PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13(7): 465477.CrossRefGoogle ScholarPubMed
54. Wonodi, I, Schwarcz, R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010; 36(2): 211218.CrossRefGoogle Scholar
55. Wonodi, I, Stine, OC, Sathyasaikumar, KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011; 68(7): 665674.CrossRefGoogle ScholarPubMed
56. Goff, DC, Lamberti, JS, Leon, AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008; 33(3): 465472.CrossRefGoogle Scholar
57. Goff, DC, Hill, M, Barch, D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99(2): 245253.CrossRefGoogle Scholar
58. Beinat, C, Banister, SD, Herrera, M, et al. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs. 2015; 29(7): 529542.CrossRefGoogle ScholarPubMed
59. Javitt, DC, Carter, CS, Krystal, JH, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018; 75(1): 1119.CrossRefGoogle ScholarPubMed

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 48
Total number of PDF views: 236 *
View data table for this chart

* Views captured on Cambridge Core between 05th June 2018 - 26th January 2021. This data will be updated every 24 hours.

Hostname: page-component-898fc554b-p5tlp Total loading time: 0.445 Render date: 2021-01-26T13:01:39.178Z Query parameters: { "hasAccess": "0", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false }

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Pharmacotherapy of schizophrenia: toward a metabolomic-based approach
Available formats

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Pharmacotherapy of schizophrenia: toward a metabolomic-based approach
Available formats

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Pharmacotherapy of schizophrenia: toward a metabolomic-based approach
Available formats

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *